We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) reported a loss of 60 cents per share for the first quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of 52 cents and the year-ago figure of 42 cents due to higher R&D costs.
Nektar’s stock was up 2.8% on May 11 following the earnings release. Shares of Nektar have outperformed the industry so far this year. The stock has risen 33% while the industry is up 0.6%.
Quarterly revenues soared 53.8% from the year-ago period to $38 million. This upside can mainly be attributed to a $10 million milestone payment under the collaboration agreement with Shire plc related to the approval of hemophilia drug, Adynovi, in Europe. The top line came in line with the Zacks Consensus Estimate.
Quarter in Detail
The top line comprised product sales, royalty revenues, non-cash royalty revenues besides license, collaboration and other revenues.
In the first quarter, product sales rose 32.4% to $6.3 million from $4.8 million a year ago. Moreover, non-cash royalty revenues increased 3.9% to $6.9 million.
The company reported royalty revenues of $11.1 million in the quarter under review, registering an improvement of 53.5% from $7.2 million a year ago.
License, collaboration and other revenues came in at $13.7 million compared with $6.1 million in the prior year, an upside of 125.3%.
Research and development (R&D) expenses escalated 62.8% to $99.4 million, primarily due to investments in pipeline including key candidates NKTR-358, NKTR-214 and NKTR-181.
General and administrative (G&A) expenses were up 56% to $18.7 million in the reported quarter primarily due to higher stock-based compensation.
Pipeline Update
The company received a major boost in February when it announced a global strategic collaboration agreement with Bristol-Myers Squibb (BMY - Free Report) . Per the agreement, the companies will jointly develop and commercialize Nektar’s lead immuno-oncology candidate, NKTR-214, in combination with Bristol-Myers’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab).
Moreover, pursuant to the contract, the company received $1.0 billion in upfront payment and proceeds of $850 million from share purchase in April.
In the same month, Nektar began dosing in a phase I/II study – REVEAL – to evaluate a combination of its two candidates NKTR-262, a toll-like receptor agonist, and NKTR-214, an immuno-stimulatory CD122-biased agonist, in advanced or metastatic solid tumor cancers.
Moreover, the company has also collaborated with Takeda to develop NKTR-214 in combination with the latter’s TAK-659, a dual SYK and FLT-3 inhibitor, in liquid and solid tumors. First study under this collaboration is expected to start in the second half of 2018, which will evaluate the combination in non-Hodgkin lymphoma.
In May, Nektar initiated a dose ranging phase Ib study to evaluate NKTR-358, a regulatory T cell stimulator, in patients with systemic lupus erythematosus, an autoimmune disease. The company has a worldwide license agreement with Eli Lilly (LLY - Free Report) related to the development of NKTR-358.
Apart from these, the company’s pipeline includes two late stage candidates, Onzeald and NKTR-181.
Onzeald is currently under evaluation in a phase III (ATTAIN) study for the treatment of adults with advanced breast cancer, having brain metastases. The company is developing NKTR-181 for the treatment of chronic pain. A new drug application is expected to be filed with the FDA this month.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
Nektar Therapeutics (NKTR - Free Report) reported a loss of 60 cents per share for the first quarter of 2018, which was wider than the Zacks Consensus Estimate of a loss of 52 cents and the year-ago figure of 42 cents due to higher R&D costs.
Nektar’s stock was up 2.8% on May 11 following the earnings release. Shares of Nektar have outperformed the industry so far this year. The stock has risen 33% while the industry is up 0.6%.
Quarterly revenues soared 53.8% from the year-ago period to $38 million. This upside can mainly be attributed to a $10 million milestone payment under the collaboration agreement with Shire plc related to the approval of hemophilia drug, Adynovi, in Europe. The top line came in line with the Zacks Consensus Estimate.
Quarter in Detail
The top line comprised product sales, royalty revenues, non-cash royalty revenues besides license, collaboration and other revenues.
In the first quarter, product sales rose 32.4% to $6.3 million from $4.8 million a year ago. Moreover, non-cash royalty revenues increased 3.9% to $6.9 million.
The company reported royalty revenues of $11.1 million in the quarter under review, registering an improvement of 53.5% from $7.2 million a year ago.
License, collaboration and other revenues came in at $13.7 million compared with $6.1 million in the prior year, an upside of 125.3%.
Research and development (R&D) expenses escalated 62.8% to $99.4 million, primarily due to investments in pipeline including key candidates NKTR-358, NKTR-214 and NKTR-181.
General and administrative (G&A) expenses were up 56% to $18.7 million in the reported quarter primarily due to higher stock-based compensation.
Pipeline Update
The company received a major boost in February when it announced a global strategic collaboration agreement with Bristol-Myers Squibb (BMY - Free Report) . Per the agreement, the companies will jointly develop and commercialize Nektar’s lead immuno-oncology candidate, NKTR-214, in combination with Bristol-Myers’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab).
Moreover, pursuant to the contract, the company received $1.0 billion in upfront payment and proceeds of $850 million from share purchase in April.
In the same month, Nektar began dosing in a phase I/II study – REVEAL – to evaluate a combination of its two candidates NKTR-262, a toll-like receptor agonist, and NKTR-214, an immuno-stimulatory CD122-biased agonist, in advanced or metastatic solid tumor cancers.
Moreover, the company has also collaborated with Takeda to develop NKTR-214 in combination with the latter’s TAK-659, a dual SYK and FLT-3 inhibitor, in liquid and solid tumors. First study under this collaboration is expected to start in the second half of 2018, which will evaluate the combination in non-Hodgkin lymphoma.
In May, Nektar initiated a dose ranging phase Ib study to evaluate NKTR-358, a regulatory T cell stimulator, in patients with systemic lupus erythematosus, an autoimmune disease. The company has a worldwide license agreement with Eli Lilly (LLY - Free Report) related to the development of NKTR-358.
Apart from these, the company’s pipeline includes two late stage candidates, Onzeald and NKTR-181.
Onzeald is currently under evaluation in a phase III (ATTAIN) study for the treatment of adults with advanced breast cancer, having brain metastases. The company is developing NKTR-181 for the treatment of chronic pain. A new drug application is expected to be filed with the FDA this month.
Nektar Therapeutics Price and EPS Surprise
Nektar Therapeutics Price and EPS Surprise | Nektar Therapeutics Quote
Zacks Rank
Nektar carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>